QRG Capital Management Inc. Grows Position in Johnson & Johnson $JNJ

QRG Capital Management Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 5.7% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 440,815 shares of the company’s stock after purchasing an additional 23,837 shares during the period. Johnson & Johnson comprises about 0.8% of QRG Capital Management Inc.’s portfolio, making the stock its 21st largest holding. QRG Capital Management Inc.’s holdings in Johnson & Johnson were worth $111,954,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of JNJ. National Pension Service boosted its stake in shares of Johnson & Johnson by 1.3% in the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after buying an additional 67,484 shares during the last quarter. IFP Advisors Inc lifted its holdings in Johnson & Johnson by 8.8% in the second quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after acquiring an additional 3,133 shares during the period. Elefante Mark B lifted its holdings in Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after acquiring an additional 2,563 shares during the period. Signal Advisors Wealth LLC boosted its position in Johnson & Johnson by 76.1% in the first quarter. Signal Advisors Wealth LLC now owns 15,126 shares of the company’s stock worth $3,697,000 after purchasing an additional 6,539 shares during the last quarter. Finally, Gradient Investments LLC grew its stake in shares of Johnson & Johnson by 9.9% during the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after purchasing an additional 13,737 shares during the period. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by corporate insiders.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New Phase 3 modeling for the TECVAYLI plus DARZALEX FASPRO combination estimated that approximately 87% of eligible relapsed/refractory multiple myeloma patients could reach mortality risk comparable to the general population. The analysis also projected nearly four times longer median survival versus standard care, supporting the long-term commercial potential of J&J’s oncology portfolio. MajesTEC-3 analysis
• Positive Sentiment: J&J’s recently approved ICOTYDE psoriasis treatment expands its immunology growth pipeline beyond oncology and MedTech. Its ongoing Phase 3 psoriatic arthritis program could provide an additional growth opportunity as STELARA sales decline after loss of exclusivity. ICOTYDE immunology push
• Positive Sentiment: Positive Phase 3 results for CAPLYTA in bipolar I mania strengthen the case that J&J’s Intra-Cellular acquisition can broaden the drug’s use beyond bipolar depression. Approval and commercial execution remain future catalysts. CAPLYTA bipolar study
• Neutral Sentiment: Analysts continue to favor J&J’s dividend durability and diversified pipeline, but the stock’s strong 12-month performance and elevated valuation may already reflect much of the expected improvement. Healthcare dividend roundup
• Negative Sentiment: Investor debate remains focused on whether portfolio streamlining, including a potential sale of the orthopedics business, can accelerate growth without sacrificing scale or future MedTech opportunities. The market’s reaction to OTTAVA also underscores the need for stronger execution in MedTech. Potential orthopedics divestiture

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded down $0.18 during midday trading on Wednesday, hitting $269.01. The stock had a trading volume of 6,371,746 shares, compared to its average volume of 8,034,880. The firm’s fifty day moving average is $264.30 and its two-hundred day moving average is $247.03. The company has a market capitalization of $648.28 billion, a PE ratio of 31.17, a P/E/G ratio of 2.57 and a beta of 0.24. Johnson & Johnson has a 52-week low of $175.74 and a 52-week high of $281.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s payout ratio is 62.11%.

Analysts Set New Price Targets

JNJ has been the topic of several recent research reports. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Bank of America upped their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a report on Friday, July 10th. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 15th. The Goldman Sachs Group reissued a “buy” rating and set a $282.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $274.13.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.